Graviti Pharmaceuticals is recalling approximately 46,512 bottles of Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, because the medication failed to meet the required tablet and capsule specifications. This medication, which is the generic version of Wellbutrin XL, was distributed in 30-count bottles to one distributor and 16 wholesalers and retailers across the country. The recall was initiated because the product did not meet established quality standards for these types of tablets.
Failure to meet tablet specifications can result in the medication not releasing correctly in the body, potentially leading to the patient receiving too much or too little of the drug at once.
You have 2 options:
Distributed by Rising Phar; Manufactured by Graviti Pharmaceuticals Private Limited.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.